AVD at a glance
AMERICAN VANGUARD CORP (AVD, SEC CIK 5981) filed its latest 10-K annual report on March 16, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 10, 2026 and Form 4 insider filings as recently as November 20, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), AMERICAN VANGUARD CORP (AVD) reported revenue of $515.1 million (down 5.9% from FY2024) and a net loss of $49.9 million. Diluted EPS was -$1.75.
- As of September 30, 2026, 19 institutional investment managers tracked by SignalX reported holding AMERICAN VANGUARD CORP (AVD) shares worth $9.8 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by ROSENBLOOM KEITH M on August 18, 2026 of 556,580 shares at $2.20 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $515.1M
- −5.9% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 19 funds
- $9.8M · −4 vs prior quarter
- Latest 8-K
- Nov 10, 2026
- Item 2.02 · Item 7.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- Newly added risk: $225,000 First Lien Term Loan requires leverage compliance dependent on significant adjusted EBITDA generation in Q4 2026
- Most materially updated financial risk: debt increased to $267,687 net, with weighted-average interest rate of 12.9% in Q3 2026
- Regulatory and legal risk: Chavez litigation trial schedule removed after summary-judgment and Daubert motions
- Operational risk: Los Angeles plant reorganization expected completion by December 31, 2026
- Market risk: International sales declined to $47,188 from $56,770 in Q3 2025
Management Discussion & Analysis
- Revenue $108,376, down 9% YoY from $119,313, with International worst at $47,188, down 17%
- Gross margin 24% vs 29% YoY; operating expenses 32% of sales vs 34%, with operating loss $7,965
- U.S. Specialty strongest nine-month segment, sales $57,045, up 6% YoY; U.S. Crop sales $157,510, up 3%
- Cash $83,909 vs $16,795, operating cash use $12,346, financing provided $93,669, including $109,875 net borrowings
- Fourth-quarter results may be meaningful, but covenant compliance requires significant adjusted EBITDA amid fuel, freight, weather and demand uncertainty
AI summary of the AVD 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Press release covers unaudited third-quarter and nine-month fiscal 2026 results through September 30, 2026
- Exhibit 99.1 contains the financial results, including revenue, earnings, cash flow and management commentary
Item 7.01: Regulation FD Disclosure
- Earnings call covered unaudited results for the three and nine months ended September 30, 2026
- Transcript available in Exhibit 99.2, providing management commentary beyond reported financial statements
Item EX-99.1: Item EX-99.1
- Q3 sales fell 9% to $108.4M, led by a 17% international decline, while U.S. sales decreased 2%
- Gross margin contracted to 24% from 29%, driving operating loss of $8.0M and net loss of $17.7M
Item EX-99.2: Item EX-99.2
- Q3 sales $108M, down 9%, with adjusted EBITDA approximately break-even, down $8.3M year-over-year
- Gross margin fell to 24.2% from 28.7%, pressured by freight costs, raw materials and weak fixed-cost absorption
Item EX-99.1: Item EX-99.1
- Matt Horwath becomes CFO October 1, 2026, replacing David Johnson in a planned leadership transition
- David Johnson remains Chief Accounting Officer through March 2027, then non-executive employment through September 2027
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Matthew Horwath appointed CFO effective October 1, 2026, bringing FARO finance, M&A, capital markets, and reporting experience
- CFO compensation: $450,000 base salary, 60% bonus target, plus $6,667 monthly relocation and $10,000 monthly travel allowances
Item 7.01: Regulation FD Disclosure
- Matthew Horwath appointed Chief Financial Officer effective October 1, 2026
- CFO transition creates potential investor focus on financial reporting, capital allocation and strategic execution
Item EX-99.2: Item EX-99.2
- Q2 sales $117M, down from $129M, with adjusted EBITDA $6.6M versus $11M, highlighting near-term volume and freight pressure
- First-half sales $240M, down 2%, while adjusted EBITDA rose over 20% to $17M, showing benefits from cost actions
Item 2.02: Results of Operations and Financial Condition
- Unaudited results cover three and six months ended June 30, 2026
- Press release issued August 10, 2026
Item 7.01: Regulation FD Disclosure
- Earnings call covered unaudited three- and six-month results ended June 30, 2026
- Transcript attached as Exhibit 99.2, providing management commentary and investor-relevant context
Item EX-99.1: Item EX-99.1
- Q2 sales fell 10% to $116.8 million, with international sales down 18% and U.S. crop sales down 9%
- Q2 net loss widened to $9.9 million from $849 thousand, while adjusted EBITDA declined to $6.6 million from $11.0 million
AI summaries of AVD 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for AVD
Don't miss the next AVD filing
- Alerts as it files. A push when AVD files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut AVD, by share count.
- Ask anything. An AI agent that reads every AVD filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Horwath Matthew | A | Oct 1, 2026 | 150,000 | - |
| Horwath Matthew | A | Oct 1, 2026 | 100,000 | - |
| ROSENBLOOM KEITH M | Sell | Aug 18, 2026 | 556,580 | $2.20 |
| Macicek Steven D | Buy | Aug 17, 2026 | 19,000 | $2.09 |
| Kaye Douglas | J | Jul 10, 2026 | 6,527 | $2.36 |
| Bassett Mark R | A | Jun 4, 2026 | 31,872 | - |
| Gottschalk Patrick E | A | Jun 4, 2026 | 31,872 | - |
| ROSENBLOOM KEITH M | A | Jun 4, 2026 | 31,872 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $547.3M | $515.1M |
| Gross Profit | $179.2M | $120.3M | $147.6M |
| Operating Income | - | -$101.6M | -$28.3M |
| Net Income | $7.5M | -$126.3M | -$49.9M |
| Gross Margin | - | 22.0% | 28.6% |
| Op. Margin | - | -18.6% | -5.5% |
| Net Margin | - | -23.1% | -9.7% |
| Balance Sheet | |||
| Total Assets | $767.5M | $636.7M | $596.5M |
| Equity | - | $233.1M | $192.4M |
| ROE | - | -54.2% | -25.9% |
| Per Share | |||
| EPS | $0.26 | $-4.50 | $-1.75 |
| Cash Flow | |||
| Operating CF | - | $3.9M | -$21.2M |
Source: XBRL data in AMERICAN VANGUARD CORP (AVD)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate AVD share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 19 | $9.8M |
| Q2 2026 | 23 | $17.6M |
| Q1 2026 | 23 | $22.0M |
| Q4 2025 | 23 | $32.4M |
| Q3 2025 | 23 | $50.8M |
| Q2 2025 | 25 | $35.6M |
| Q1 2025 | 23 | $33.7M |
| Q4 2024 | 18 | $30.5M |
- Prudential Financial+129.4K (+814%)
- D.E. Shaw & Co+104.1K (+20%)
- Citadel Advisors LLC+88.4K (+209%)
- BlackRock+76.6K (+8%)
- Two Sigma Investments+25.2K (+3%)
- AQR Capital Management−278.6K (-75%)
- Dimensional Fund Advisors−215.1K (-28%)
- Morgan Stanley−130.6K (-62%)
- Millennium Management−80.5K (-40%)
- JPMorgan Chase & Co−63.7K (-35%)
- FMR LLC (Fidelity)−294.9K
- StoneX Group Inc.−12.5K
- Wells Fargo & Co−3.0K
- PNC Financial Services−135
- Citigroup−1
Source: 13F-HR filings on SEC EDGAR (aggregated from 177 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
AVD filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 20, 2026 | - | - | - |
| 8-K | Nov 10, 2026 | - | Analysis | - |
| 10-Q | Nov 9, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Oct 1, 2026 | - | Analysis | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 8-K | Aug 11, 2026 | - | Analysis | - |
| 10-Q | Aug 10, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jul 14, 2026 | - | - | - |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 8-K | Jun 8, 2026 | - | Analysis | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 4, 2026 | - | - | |
| 4 | May 19, 2026 | - | - |
Related Health Care companies
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ABSI · Absci CorpServices-Commercial Physical & Biological Research
- ACHC · Acadia Healthcare Company IncServices-Specialty Outpatient Facilities, NEC
AVD SEC filings: frequently asked questions
Which institutions hold AVD stock?
As of September 30, 2026, the largest AMERICAN VANGUARD CORP (AVD) holders among the 13F filers tracked by SignalX were Vanguard Capital Management LLC ($2.0 million), BlackRock ($1.8 million), Two Sigma Investments ($1.3 million), D.E. Shaw & Co ($1.1 million), Dimensional Fund Advisors ($980,000). 13F-HR reports are filed up to 45 days after each quarter ends.
What was AVD's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), AMERICAN VANGUARD CORP (AVD) reported revenue of $515.1 million (down 5.9% from FY2024) and a net loss of $49.9 million. Diluted EPS was -$1.75. The figures come from the XBRL data in the 10-K.
What did AVD report in its latest 8-K?
AMERICAN VANGUARD CORP (AVD) filed an 8-K on November 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure). Press release covers unaudited third-quarter and nine-month fiscal 2026 results through September 30, 2026.
What are the latest AVD SEC filings?
AMERICAN VANGUARD CORP (AVD) filed its latest 10-K annual report on March 16, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 10, 2026 and a Form 4 insider filing on November 20, 2026.
What is AVD's SEC CIK number?
AMERICAN VANGUARD CORP (AVD)'s SEC Central Index Key (CIK) is 5981. EDGAR lists every AVD filing under that number.
Ask anything about AVD
The research agent reads AVD's filings, financials, insider trades and 13F holders, then answers with sources.